Aplastic Anemia induced by Nivolumab before a Treatment of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
As an Immune checkpoint blockade therapy (ICB), nivolumab has demonstrated efficacy in Acute Myeloid Leukemia (AML) and various other malignancies. Nivolumab is used as an anti-programmed cell death 1 (PD-1) agent. The toxicities are observed in more than 10% of patients, because of its ability,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2019-08-01
|
| Series: | BioDiscovery |
| Subjects: | |
| Online Access: | https://biodiscovery.pensoft.net/article/37211/download/pdf/ |